This review examines currently available evidence and theoretical considerations to advise patients with high-risk chronic lymphocytic leukemia (CLL) about the indication and timing of HCT versus the administration of novel classes of drugs such as BCR-signal inhibitors and BCL2 antagonists. The authors propose that all patients with high-risk CLL be considered for treatment with these novel agents along with discussion of HCT options for those patients responding or not responding to them.
High-Risk CLL: Current Treatment Considerations with Novel Agents and HCT
Oct 2014